Detail akcie AbCellera Biolog Rg online

Business Summary: AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, AbCellera Biologics Inc revenues increased 27% to $30.3M. Net loss increased 7% to $137.5M. Revenues reflect Licensing revenue segment increase from $370K to $10.6M, Research fees segment increase from $5.5M to $15.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.44 to -$0.46.